S&P Capital IQ rates the $151.1 million RCD marketweight. The fund is lower this year, although it slightly outpaced some of its cap-weighted rivals in 2013. The research firm also has a marketweight rating on the $397.2 million Guggenheim S&P Equal Weight Technology ETF (NYSEArca: RYT).

RYT is home to many of the tech and Internet stocks investors have come to love, including Facebook (NasdaqGM: FB), Google (NasdaqGM: GOOG) and Apple (NasdaqGM: AAPL), but those stocks do not even combine for 4.5% of the fund’s weight.

Although the equal weight strategy diminishes RYT’s leverage to large pops in a particular stock, such as the one recently seen in Google, the ETF crushed its cap-weighted rivals last year and has been less bad than those competitors this year. [Google and ETFs]

S&P Capital IQ has an overweight rating on the Guggenheim S&P Equal Weight Healthcare ETF (NYSEArca: RYH).

The $147.1 million RYH is underweight pharmaceuticals and biotech stocks compared to its cap-weighted peers, but the ETF features higher allocations to equipment, services and life sciences providers. All of those sub-sectors have helped bolster the broader health care group this year. [Health Care ETFs Still Delivering]


Tom Lydon’s clients own shares of RSP, Apple, Google and Facebook.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.